These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37532782)

  • 21. Baricitinib, a Janus kinase inhibitor, in the treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials.
    Kunwar S; Collins CE; Constantinescu F
    Clin Rheumatol; 2018 Oct; 37(10):2611-2620. PubMed ID: 30006916
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study.
    Le Voyer T; Gitiaux C; Authier FJ; Bodemer C; Melki I; Quartier P; Aeschlimann F; Isapof A; Herbeuval JP; Bondet V; Charuel JL; Frémond ML; Duffy D; Rodero MP; Bader-Meunier B
    Rheumatology (Oxford); 2021 Dec; 60(12):5801-5808. PubMed ID: 33576769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of tofacitinib versus baricitinib in patients with rheumatoid arthritis in real clinical practice: analyses with propensity score-based inverse probability of treatment weighting.
    Miyazaki Y; Nakano K; Nakayamada S; Kubo S; Inoue Y; Fujino Y; Tanaka Y
    Ann Rheum Dis; 2021 Sep; 80(9):1130-1136. PubMed ID: 33827788
    [TBL] [Abstract][Full Text] [Related]  

  • 24. National and interprovincial prescribing patterns of JAK-inhibitors in Canada: a repeated cross-sectional analysis.
    Saunders KC; Shakeri A; Chu C; Drucker AM; Tadrous M
    Clin Rheumatol; 2024 Oct; 43(10):3083-3088. PubMed ID: 39198358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Janus kinase inhibitors: An innovative treatment for alopecia areata.
    Park H; Yu DA; Kwon O
    J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib.
    Xia D; Xiao Y; Li M; Li W
    Dermatol Ther; 2022 Sep; 35(9):e15724. PubMed ID: 35855568
    [No Abstract]   [Full Text] [Related]  

  • 27. Conversion of Functional Assessment of Chronic Illness Therapy-Fatigue to Patient-Reported Outcomes Measurement Information System Fatigue Scores in Two Phase III Baricitinib Rheumatoid Arthritis Trials.
    Bingham CO; Bartlett SJ; Kannowski C; Sun L; DeLozier AM; Cella D
    Arthritis Care Res (Hoboken); 2021 Apr; 73(4):481-488. PubMed ID: 31961494
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic changes from type I interferons and JAK inhibitors: clues to drivers of juvenile dermatomyositis.
    Covert LT; Prinz JA; Swain-Lenz D; Dvergsten J; Truskey GA
    Rheumatology (Oxford); 2024 Sep; 63(SI2):SI240-SI248. PubMed ID: 38317053
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rapid improvement of refractory generalized granuloma annulare with the Janus kinase inhibitor baricitinib in two patients.
    Kim D; Kang HY
    Clin Exp Dermatol; 2023 Mar; 48(4):375-376. PubMed ID: 36763768
    [No Abstract]   [Full Text] [Related]  

  • 30. [Janus kinase inhibitor baricitinib for rheumatoid arthritis : Randomized, double-blind, placebo- and active-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy (RA-BEAM)].
    Alten R; Nitschmann S
    Internist (Berl); 2017 Dec; 58(12):1341-1344. PubMed ID: 29119202
    [No Abstract]   [Full Text] [Related]  

  • 31. Epidermolysis Bullosa Pruriginosa treated with baricitinib: A case report.
    He Z; Dong Q; Xi Y; Zheng R
    Medicine (Baltimore); 2024 Jul; 103(27):e38854. PubMed ID: 38968458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1).
    Meesilpavikkai K; Dik WA; Schrijver B; Nagtzaam NMA; Posthumus-van Sluijs SJ; van Hagen PM; Dalm VASH
    J Allergy Clin Immunol; 2018 Jul; 142(1):328-330.e2. PubMed ID: 29729898
    [No Abstract]   [Full Text] [Related]  

  • 33. HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19.
    Spinelli FR; Conti F; Gadina M
    Sci Immunol; 2020 May; 5(47):. PubMed ID: 32385052
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Janus kinase inhibitor (baricitinib) suppresses the rheumatoid arthritis active marker gliostatin/thymidine phosphorylase in human fibroblast-like synoviocytes.
    Joyo Y; Kawaguchi Y; Yonezu H; Senda H; Yasuma S; Shiraga H; Nozaki M; Aoyama M; Asai K; Murakami H; Waguri-Nagaya Y
    Immunol Res; 2022 Apr; 70(2):208-215. PubMed ID: 35014010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical significance of Janus Kinase inhibitor selectivity.
    Choy EH
    Rheumatology (Oxford); 2019 Jun; 58(6):953-962. PubMed ID: 30508136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A case of widespread molluscum contagiosum caused by baricitinib, a Janus kinase inhibitor.
    Wong GN; Lee S; Foley P
    Australas J Dermatol; 2019 Nov; 60(4):e334-e335. PubMed ID: 31012089
    [No Abstract]   [Full Text] [Related]  

  • 37. A case of hemophagocytic lymphohistiocytosis with a significant response to baricitinib: a first report with review of literature.
    Irino K; Jinnouchi F; Nakano S; Sawabe T
    Clin Rheumatol; 2023 Jul; 42(7):1959-1963. PubMed ID: 36947281
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis.
    Kim H; Dill S; O'Brien M; Vian L; Li X; Manukyan M; Jain M; Adeojo LW; George J; Perez M; Grom AA; Sutter M; Feldman BM; Yao L; Millwood M; Brundidge A; Pichard DC; Cowen EW; Shi Y; Lu S; Tsai WL; Gadina M; Rider LG; Colbert RA
    Ann Rheum Dis; 2021 Mar; 80(3):406-408. PubMed ID: 32843325
    [No Abstract]   [Full Text] [Related]  

  • 39. Improvement of cutaneous inflammation and panniculitis in patients with dermatomyositis by the Janus kinase inhibitor baricitinib.
    Fischer K; Aringer M; Steininger J; Heil J; Beissert S; Abraham S; Günther C
    Br J Dermatol; 2022 Sep; 187(3):432-435. PubMed ID: 35318646
    [No Abstract]   [Full Text] [Related]  

  • 40. Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.
    Ebina K; Hirano T; Maeda Y; Yamamoto W; Hashimoto M; Murata K; Onishi A; Jinno S; Hara R; Son Y; Amuro H; Takeuchi T; Yoshikawa A; Katayama M; Yamamoto K; Okita Y; Hirao M; Etani Y; Kumanogoh A; Okada S; Nakata K
    Sci Rep; 2022 Jan; 12(1):134. PubMed ID: 34997059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.